Our commitment starts here.
Find. Fight. Follow.™
Our commitment starts here.
Find. Fight. Follow.™
Our commitment starts here.
Find. Fight. Follow.™
Data provided by Nasdaq.
Minimum 15 minutes delayed.
For more than half a century, our diagnostic and therapeutic innovations have changed the way clinicians Find, Fight and Follow® disease. Today, we go further still—with the same sense of purpose and commitment to empowering healthcare professionals with life-changing science that helps improve outcomes and lives.
Phase III clinical trial of [ 18 F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy for [ 18 F]flurpiridaz PET compared to SPECT Myocardial
Read MoreNORTH BILLERICA, Mass. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative diagnostics, targeted therapeutics and artificial intelligence solutions that empower clinicians to Find,
Read MoreWorldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year period GAAP net income of $43.1 million for the second quarter 2022, compared to GAAP net loss of $26.7 million in the prior year period GAAP fully diluted net income per share of
Read MoreNORTH BILLERICA, Mass. , July 21, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 4, 2022 , to discuss its financial and operating results for the second quarter of
Read More